Shares of Divis Laboratories declined by as much as 4.2% to an intraday low of Rs 6,545.00 in early trade, before partially recovering losses. At 10.15 am, the stock was trading down 2% at Rs 6,702, reflecting a negative sentiment in the market. Divis Laboratories is included as one of the stocks in the NIFTY NEXT 50 index.
Financial Performance:
Divis Laboratories' financial performance shows consistent growth in revenue and net profit. Here's an overview of the company's consolidated financial data:
Quarterly Results:
The quarterly financial performance of Divis Laboratories indicates a steady increase in both revenue and net profit across the quarters.
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,303.00 Crore | Rs 2,118.00 Crore | Rs 2,338.00 Crore | Rs 2,319.00 Crore | Rs 2,585.00 Crore |
| Net Profit | Rs 538.00 Crore | Rs 430.00 Crore | Rs 510.00 Crore | Rs 589.00 Crore | Rs 662.00 Crore |
| EPS | 20.25 | 16.20 | 19.20 | 22.20 | 24.93 |
The revenue for the quarter-ending March 2025 stood at Rs 2,585.00 Crore, up from Rs 2,303.00 Crore in March 2024. The net profit for the same period increased from Rs 538.00 Crore to Rs 662.00 Crore. Earnings per share (EPS) also rose from 20.25 to 24.93.
Annual Results:
The yearly financial performance demonstrates consistent growth in revenue and net profit.
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 6,969.40 Crore | Rs 8,959.83 Crore | Rs 7,767.51 Crore | Rs 7,845.00 Crore | Rs 9,360.00 Crore |
| Net Profit | Rs 1,984.29 Crore | Rs 2,960.45 Crore | Rs 1,823.38 Crore | Rs 1,600.00 Crore | Rs 2,191.00 Crore |
| EPS | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| BVPS | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| ROE | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The revenue for the year-ending March 2025 increased to Rs 9,360.00 Crore from Rs 7,845.00 Crore in March 2024. The net profit also rose to Rs 2,191.00 Crore from Rs 1,600.00 Crore. The Earnings per share (EPS) increased from Rs 60.27 to Rs 82.53.
Income Statement:
The income statement provides a detailed breakdown of Divis Laboratories' financial performance over the past five years.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 9,360 Crore | Rs 7,845 Crore | Rs 7,767 Crore | Rs 8,959 Crore | Rs 6,969 Crore |
| Other Income | Rs 352 Crore | Rs 339 Crore | Rs 344 Crore | Rs 113 Crore | Rs 62 Crore |
| Total Income | Rs 9,712 Crore | Rs 8,184 Crore | Rs 8,112 Crore | Rs 9,073 Crore | Rs 7,031 Crore |
| Total Expenditure | Rs 6,794 Crore | Rs 6,018 Crore | Rs 5,742 Crore | Rs 5,389 Crore | Rs 4,365 Crore |
| EBIT | Rs 2,918 Crore | Rs 2,166 Crore | Rs 2,369 Crore | Rs 3,684 Crore | Rs 2,666 Crore |
| Interest | Rs 2 Crore | Rs 3 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore |
| Tax | Rs 725 Crore | Rs 563 Crore | Rs 545 Crore | Rs 723 Crore | Rs 681 Crore |
| Net Profit | Rs 2,191 Crore | Rs 1,600 Crore | Rs 1,823 Crore | Rs 2,960 Crore | Rs 1,984 Crore |
Sales increased from Rs 7,845 Crore in March 2024 to Rs 9,360 Crore in March 2025. Total expenditure also saw an increase from Rs 6,018 Crore to Rs 6,794 Crore. The net profit increased from Rs 1,600 Crore in March 2024 to Rs 2,191 Crore in March 2025.
Quarterly Income Statement:
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 2,585 Crore | Rs 2,319 Crore | Rs 2,338 Crore | Rs 2,118 Crore | Rs 2,303 Crore |
| Other Income | Rs 86 Crore | Rs 82 Crore | Rs 106 Crore | Rs 79 Crore | Rs 79 Crore |
| Total Income | Rs 2,671 Crore | Rs 2,401 Crore | Rs 2,444 Crore | Rs 2,197 Crore | Rs 2,382 Crore |
| Total Expenditure | Rs 1,806 Crore | Rs 1,675 Crore | Rs 1,721 Crore | Rs 1,593 Crore | Rs 1,667 Crore |
| EBIT | Rs 865 Crore | Rs 726 Crore | Rs 723 Crore | Rs 604 Crore | Rs 715 Crore |
| Interest | Rs 1 Crore | Rs 0 Crore | Rs 1 Crore | Rs 0 Crore | Rs 2 Crore |
| Tax | Rs 202 Crore | Rs 137 Crore | Rs 212 Crore | Rs 174 Crore | Rs 175 Crore |
| Net Profit | Rs 662 Crore | Rs 589 Crore | Rs 510 Crore | Rs 430 Crore | Rs 538 Crore |
Sales increased from Rs 2,303 Crore in March 2024 to Rs 2,585 Crore in March 2025. Total expenditure also saw an increase from Rs 1,667 Crore to Rs 1,806 Crore. The net profit increased from Rs 538 Crore in March 2024 to Rs 662 Crore in March 2025.
Cash Flow:
Cash flow provides an overview of the company's sources and uses of cash.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,653 Crore | Rs 1,261 Crore | Rs 2,459 Crore | Rs 1,911 Crore | Rs 1,946 Crore |
| Investing Activities | Rs -804 Crore | Rs -269 Crore | Rs -2,707 Crore | Rs -2,194 Crore | Rs 75 Crore |
| Financing Activities | Rs -799 Crore | Rs -799 Crore | Rs -797 Crore | Rs -532 Crore | Rs -34 Crore |
| Others | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 50 Crore | Rs 193 Crore | Rs -1,045 Crore | Rs -815 Crore | Rs 1,987 Crore |
The balance sheet provides a snapshot of the company's assets, liabilities, and equity.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 53 Crore | Rs 53 Crore | Rs 53 Crore | Rs 53 Crore | Rs 53 Crore |
| Reserves & Surplus | Rs 14,916 Crore | Rs 13,518 Crore | Rs 12,714 Crore | Rs 11,675 Crore | Rs 9,241 Crore |
| Current Liabilities | Rs 1,452 Crore | Rs 1,278 Crore | Rs 1,101 Crore | Rs 1,195 Crore | Rs 1,112 Crore |
| Other Liabilities | Rs 511 Crore | Rs 621 Crore | Rs 570 Crore | Rs 450 Crore | Rs 367 Crore |
| Total Liabilities | Rs 16,932 Crore | Rs 15,470 Crore | Rs 14,438 Crore | Rs 13,374 Crore | Rs 10,774 Crore |
| Fixed Assets | Rs 6,463 Crore | Rs 5,517 Crore | Rs 4,934 Crore | Rs 4,794 Crore | Rs 4,414 Crore |
| Current Assets | Rs 10,081 Crore | Rs 9,675 Crore | Rs 9,311 Crore | Rs 8,351 Crore | Rs 6,174 Crore |
| Other Assets | Rs 388 Crore | Rs 278 Crore | Rs 192 Crore | Rs 228 Crore | Rs 184 Crore |
| Total Assets | Rs 16,932 Crore | Rs 15,470 Crore | Rs 14,438 Crore | Rs 13,374 Crore | Rs 10,774 Crore |
| Contingent Liabilities | Rs 0 Crore | Rs 1,432 Crore | Rs 736 Crore | Rs 1,259 Crore | Rs 1,107 Crore |
The financial ratios provide insights into the company's performance and financial health.
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Diluted Eps (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Book Value /Share (Rs.) | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| Dividend/Share (Rs.) | 20.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Face Value | 2 | 2 | 2 | 2 | 2 |
| Gross Profit Margin (%) | 41.93 | 44.59 | 34.92 | 32.42 | 35.47 |
| Operating Margin (%) | 38.26 | 41.12 | 30.50 | 27.60 | 31.17 |
| Net Profit Margin (%) | 28.47 | 33.04 | 23.47 | 20.39 | 23.40 |
| Return on Equity (%) | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| ROCE (%) | 27.60 | 30.25 | 17.76 | 15.26 | 18.85 |
| Return On Assets (%) | 18.41 | 22.13 | 12.62 | 10.34 | 12.93 |
| Current Ratio (X) | 5.55 | 6.99 | 8.46 | 7.57 | 6.94 |
| Quick Ratio (X) | 3.62 | 4.62 | 5.73 | 5.08 | 4.71 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 3,065.41 | 4,994.76 | 4,048.48 | 848.00 | 1,660.00 |
| Asset Turnover Ratio (%) | 64.68 | 0.74 | 0.56 | 0.52 | 0.58 |
| Inventory Turnover Ratio (X) | 3.25 | 1.44 | 1.03 | 1.05 | 1.19 |
| 3 Yr CAGR Sales (%) | 33.83 | 34.59 | 20.00 | 6.10 | 2.21 |
| 3 Yr CAGR Net Profit (%) | 50.42 | 47.94 | 15.09 | -10.20 | -13.97 |
| P/E (x) | 48.47 | 39.47 | 41.10 | 57.16 | 69.98 |
| P/B (x) | 10.37 | 9.97 | 5.88 | 6.71 | 10.22 |
| EV/EBITDA (x) | 32.23 | 28.55 | 26.10 | 34.24 | 44.96 |
| P/S (x) | 13.83 | 13.05 | 9.66 | 11.61 | 16.34 |
Divis Laboratories has announced several corporate actions, including dividend payouts and bonus issues.
- Dividends: The company has consistently paid dividends. A final dividend of Rs.30.00 per share (1500%) was announced on May 19, 2025, with an effective date of July 25, 2025.
- Bonus Issues: Divis Laboratories has issued bonus shares in the past, with bonus ratios of 1:1 announced on August 8, 2015, and June 6, 2009.
Divis Laboratories announced newspaper publication regarding the 35th AGM and record date for dividend and other information on July 11, 2025. The company communicated information to shareholders regarding deduction of income tax at source from payment of dividend for the financial year 2024-25 on May 29, 2025.
Divis Laboratories' stock movement reflects the early market sentiment.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
